ArticleScientific reports2025
Validation of a potency assay for CD34 + cell based therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Next-Generation GLP-1 Agonist Bioassays: Integrating Precision with Biological Relevance.International journal of molecular sciences · 2026Article
- Development of Potency Assays for Therapeutic EVs: The Art of Congruence.Journal of extracellular vesicles · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ProtheraCytes (expanded autologous CD34 + cells) promote regeneration by revascularising damaged myocardial tissue via angiogenesis through the secretion of vascular endothelium growth factor (VEGF). We developed a potency assay based on the quantification of the secreted VEGF during the expansion of CD34 + cells via an automated ELISA system (ELLA). This potency assay is fast, reliable, and quantitative assay that allows for the timely batch release before ProtheraCytes are shipped to the clinic for injection. Here, we describe the validation of the VEGF potency assay according to international guidelines for cell therapy products. The assay showed a linear response for the range [20 pg/mL - 2800 pg/mL] with a correlation coefficient R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.